Information updates

New and updated ASCIA information on subcutaneous immunoglobulin (SCIg) therapy and primary immunodeficiency (PID)

August 3, 2017: 

New and updated information on SCIg therapy and PID has been developed by ASCIA in 2017, as part of a comprehensive project. 

The aim of the following information is to assist patients with PID and their carers, and support health professionals who care for patients with PID:

Immunoglobulins (commonly known as antibodies) are used to treat adults and children with primary immune deficiencies (and other medical conditions), who are unable to make enough of their own antibodies, or who have antibodies that don’t work properly.  Replacing these antibodies helps to protect against infection and can prevent long term damage from ongoing infections, such as chronic lung disease.

Immunoglobulin replacement therapy may be given as:

  • intravenous immunoglobulin (IVIg) by injecting into the vein, usually monthly in hospital; or
  • subcutaneous immunoglobulin (SCIg) by injecting under the skin, usually 1-3 times per week. SCIg can be given at home by the patient or carer, using a mechanical infusion pump (spring loaded or battery powered) or by rapid push (a manual method that does not require a pump - infusion is pushed by hand through a syringe).

Whilst there are multiple brands that may change over time and rates of administration vary for different products, both IVIg and SCIg:

  • Are effective at reducing infections and hospitalisations
  • Preserve organ function and reduce long term damage from recurrent infections
  • Are associated with significant benefits to patient quality of life
  • Improve the lifespan of patients

Content updatd 3 August 2017

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.